Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.
Merino JL, Lip GYH, Heidbuchel H, Cohen AA, De Caterina R, de Groot JR, Ezekowitz MD, Le Heuzey JY, Themistoclakis S, Jin J, Melino M, Winters SM, Merkely B, Goette A. Merino JL, et al. Among authors: de groot jr, de caterina r. Europace. 2019 Nov 1;21(11):1633-1638. doi: 10.1093/europace/euz213. Europace. 2019. PMID: 31436835 Free PMC article. Clinical Trial.
Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension.
Hardziyenka M, Surie S, de Groot JR, de Bruin-Bon HA, Knops RE, Remmelink M, Yong ZY, Baan J Jr, Bouma BJ, Bresser P, Tan HL. Hardziyenka M, et al. Among authors: de groot jr, de bruin bon ha. Europace. 2011 Dec;13(12):1753-9. doi: 10.1093/europace/eur189. Epub 2011 Jul 21. Europace. 2011. PMID: 21784747
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY; ENSURE-AF investigators. Goette A, et al. Among authors: de groot jr. Lancet. 2016 Oct 22;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. Epub 2016 Aug 30. Lancet. 2016. PMID: 27590218 Clinical Trial.
Cardiac resynchronization therapy in adults with congenital heart disease.
Koyak Z, de Groot JR, Krimly A, Mackay TM, Bouma BJ, Silversides CK, Oechslin EN, Hoke U, van Erven L, Budts W, Van Gelder IC, Mulder BJM, Harris L. Koyak Z, et al. Among authors: de groot jr. Europace. 2018 Feb 1;20(2):315-322. doi: 10.1093/europace/euw386. Europace. 2018. PMID: 28108550
Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF).
Lip GYH, Merino JL, Banach M, de Groot JR, Maier LS, Themistoclakis S, Boriani G, Jin J, Melino M, Winters SM, Goette A. Lip GYH, et al. Among authors: de groot jr. Am J Cardiol. 2019 Feb 15;123(4):592-597. doi: 10.1016/j.amjcard.2018.11.019. Epub 2018 Nov 24. Am J Cardiol. 2019. PMID: 30527775 Clinical Trial.
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators. De Caterina R, et al. Among authors: de asmundis c, de groot jr. J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104. doi: 10.2459/JCM.0000000000000737. J Cardiovasc Med (Hagerstown). 2019. PMID: 30540648 Free article.
229 results